GGrantIndex
Sort

15,273 grants matching antimicrobial resistance

Neuronal Latency and Toxoplasma

$748,925
Christopher A Hunter · University Of Pennsylvania · R01 · FY2021 · AI

Triple-enriched metagenomics for robust resistome analysis

$748,594
Noelle Noyes · University Of Minnesota · R01 · FY2025 · AI

Monoclonal Antibody Therapeutics for Candida auris

$748,593
Arturo Casadevall · Johns Hopkins University · U19 · FY2025 · AI

Multiscale modeling of the battle over iron in invasive lung infection

$748,326
Reinhard Laubenbacher · University Of Florida · R01 · FY2021 · AI

A Scalable Platform to Discover Antimicrobials of Ribosomal Origin

$748,142
Huimin Zhao · University Of Illinois At Urbana-Champaign · R01 · FY2021 · AI

Development of validated probes for the bacterial type III secretion system

$748,102
Victoria Auerbuch Stone · University Of California Santa Cruz · R01 · FY2020 · AI

LpxH Inhibitors as Novel Therapeutics Against Multidrug-resistant Enterobacterales

$747,763
Pei Zhou · Duke University · R01 · FY2025 · AI

Development of validated probes for the bacterial type III secretion system

$747,759
Victoria Auerbuch Stone · University Of California Santa Cruz · R01 · FY2021 · AI

Determinants of S. aureus Colonization in Atopic Dermatitis

$747,753
Donald Ym Leung · National Jewish Health · U19 · FY2017 · AI

Molecular Clonality of Uropathogenic E. Coli

$747,716
Evgeni Veniaminovic Sokurenko · University Of Washington · R01 · FY2021 · AI

Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation

$747,665
Carl F Nathan · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · AI

Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation

$747,665
Carl F Nathan · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · AI

Host-directed therapy of tuberculosis: Rescuing macrophages and enhancing their activation

$747,665
Carl F Nathan · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · AI

Proteostasis in Plasmodium falciparum artemisinin resistance

$747,604
Caroline L Ng · University Of Nebraska Medical Center · R01 · FY2025 · AI

Ultrathin dissolvable antibiofilm wound contact dressing with silver and gallium

$747,426
Ankit Agarwal · Imbed Biosciences, Inc. · R44 · FY2019 · AR

VENOUS: A translational study of enterococcal bacteremia

$747,390
Cesar Augusto Arias · Methodist Hospital Research Institute · R01 · FY2024 · AI

IgM in the regulation of TB immunity

$747,370
John R. Chan · Rbhs-New Jersey Medical School · R01 · FY2022 · AI

Targeted antibiotic therapy for Shigella among children in low-resource settings

$746,813
Elizabeth Tacket Rogawski McQuade · Emory University · R01 · FY2024 · AI

Developing therapeutics to treat chronic infections

$746,404
Richard Edward Lee · St. Jude Children'S Research Hospital · R01 · FY2014 · AI

Proteostasis in Plasmodium falciparum artemisinin resistance

$746,268
Caroline L Ng · University Of Nebraska Medical Center · R01 · FY2024 · AI

A robust heterologous expression system of intact fungal secondary metabolite gene clusters for natural product discovery in Aspergillus nidulans

$746,230
Chengcang Charles Wu · Intact Genomics, Inc. · R44 · FY2019 · AT

HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension

$746,137
Paul B Yu · Vascular Biosciences · R42 · FY2019 · HL

A Scalable Platform to Discover Antimicrobials of Ribosomal Origin

$746,060
Huimin Zhao · University Of Illinois At Urbana-Champaign · R01 · FY2019 · AI

The clinical and molecular epidemiology of colistin-resistant carbapenem-resistant Enterobacteriaceae (CRE) in long-term acute care hospitals (LTACHs)

$746,005
Ebbing Lautenbach · University Of Pennsylvania · R01 · FY2023 · AI

Longitudinal Study of the Vaginal Microbiome Prior To Incident STI

$745,886
Rebecca M. Brotman · University Of Maryland Baltimore · R01 · FY2015 · AI